Investor Relations

Latest News

Jul 10, 2020

Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

View Press Release

Jul 8, 2020

Qualigen Therapeutics, Inc. Announces $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 7, 2020

Qualigen Therapeutics Engages NFL Hall of Famer Mike Haynes as Advisor to the Company and Spokesman for the FastPack® Rapid Diagnostic System "Which Saved My Life"

View All News

Corporate Presentation

View Presentation

Company Overview

Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.

View Management Team View Board of Directors

Investor Contact Information

Company

Qualigen Therapeutics, Inc.
2042 Corte del Nogal
Suite B
Carlsbad, CA 92011
T: 760-918-9165
F: 760-918-9127
info@qualigeninc.com